Cyclosporin A,mycophenolate mofetil,Methotrexate — Competitive Intelligence Brief

Cyclosporin A,mycophenolate mofetil,Methotrexate (Cyclosporin A,mycophenolate mofetil,Methotrexate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination therapy. Area: Immunology.

phase 3 Immunosuppressive combination therapy Calcineurin, IMPDH, dihydrofolate reductase Immunology Small molecule

Target snapshot

Cyclosporin A,mycophenolate mofetil,Methotrexate (Cyclosporin A,mycophenolate mofetil,Methotrexate) — Guangxi Medical University. This triple immunosuppressive combination inhibits T-cell activation and proliferation through calcineurin inhibition, inosine monophosphate dehydrogenase inhibition, and folate antagonism.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclosporin A,mycophenolate mofetil,Methotrexate TARGET	Cyclosporin A,mycophenolate mofetil,Methotrexate	Guangxi Medical University	phase 3	Immunosuppressive combination therapy	Calcineurin, IMPDH, dihydrofolate reductase
Basiliximab, Tacrolimus, MMF	Basiliximab, Tacrolimus, MMF	University Hospital Freiburg	marketed	Immunosuppressive combination therapy	IL-2 receptor (basiliximab); calcineurin (tacrolimus); IMPDH (MMF)
Everolimus+Tacrolimus+Prednisone	Everolimus+Tacrolimus+Prednisone	Fundação Pró Rim	marketed	Immunosuppressive combination therapy	mTOR (everolimus), calcineurin (tacrolimus), glucocorticoid receptor (prednisone)
Mycophenolate+Tacrolimus+Prednisone	Mycophenolate+Tacrolimus+Prednisone	Fundação Pró Rim	marketed	Immunosuppressive combination therapy	T-cell proliferation and activation (multiple targets: IMPDH, calcineurin, glucocorticoid receptor)
ATG+mycophénolate mofétil+tacrolimus	ATG+mycophénolate mofétil+tacrolimus	University Hospital, Toulouse	marketed	Immunosuppressive combination therapy	T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
Kidney transplant maintenance immunosuppression	Kidney transplant maintenance immunosuppression	Imperial College Healthcare NHS Trust	marketed	Immunosuppressive combination therapy
Cyclophosphamide, Azathioprine,prednisone,methylprednisolone	Cyclophosphamide, Azathioprine,prednisone,methylprednisolone	Assistance Publique - Hôpitaux de Paris	marketed	Immunosuppressive combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination therapy class)

1. University Hospital, Brest · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Fundação Pró Rim · 2 drugs in this class
4. Haukeland University Hospital · 1 drug in this class
5. Imperial College Healthcare NHS Trust · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Novartis · 1 drug in this class
8. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. Swiss Cancer Institute · 1 drug in this class
10. University Hospital Freiburg · 1 drug in this class